Open Orphan #ORPH – Final results Reveal Record revenues and EBITDA-profitability accompanied by significant operational progress

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited final results for the 12 months ended 31 December 2021. Financial highlights ·       Record revenues of £39.0m (2020: £22.2m) achieved representing 76% growth ·       […]

#POLB Poolbeg Pharma – TR-1: Notification of major interest in shares

TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Poolbeg Pharma PLC 1b. Please indicate if the issuer is […]

Poolbeg Pharma #POLB to engage with key international stakeholders at European Melioidosis Congress as it develops an intramuscular Melioidosis vaccine candidate

11 May 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz, Austria, as it develops a […]

Poolbeg Pharma #POLB presenting at LSX Leaders event

Today Poolbeg Pharma #POLB will be attending the LSX Leaders event & CEO Jeremy Skillington will be presenting the Poolbeg Pharma story, including how we are aspiring to become a one-stop-shop for Big Pharma seeking mid-stage products to license or acquire.

Quoted Micro 18 April 2022

AQUIS STOCK EXCHANGE Brewer Adnams (ADB) increased its revenues from £50.7m to £57.4m in 2021 and the loss was reduced from £4.3m to £1.39m. There is no final dividend. Net bank debt was £11m. The pension liability more than halved from £11.2m to £5m. Beer volumes were maintained. S-Ventures (SVEN) says headwinds in the economy […]

Open Orphan #ORPH – Proposal to purchase Poolbeg Pharma shares from distribution in specie shareholders

Open Orphan (ORPH) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 11 April 2022 from Poolbeg Pharma plc (“Poolbeg”), regarding a number of new investors (“New Investors”) having expressed interest in acquiring up to £1.6m of […]

Poolbeg Pharma #POLB commences trading on OTCQB Market in the United States

30 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that trading in the Company’s Ordinary Shares of nominal value of £0.02 each (“Ordinary Shares”) will commence today on the OTCQB Venture Market in the United States. The […]